IVF — INVO Fertility, Inc.

Summary of INVO Bioscience Q2 2023 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q2 2023 revenue totaled approximately $316,000, up 116% from $146,000 in Q2 2022. Consolidated service revenue from the Atlanta INVO Center accounted for about 81% of this total.
• Clinic Revenue: Revenue from all three operating clinics (Birmingham, Atlanta, Monterrey) reached $712,000, a 145% increase year-over-year.
• Operating Expenses: Decreased to approximately $2.4 million from $2.8 million in the prior year, attributed to lower personnel, marketing, and R&D costs.
• Adjusted EBITDA Loss: Improved to approximately $1.6 million from a loss of $2.2 million in the previous year.
• Cash Position: As of June 30, 2023, cash stood at approximately $112,000, with $1.3 million in debt. The company raised approximately $4.5 million in a public offering during the quarter.

2. Strategic Updates and Business Highlights

• Acquisition: INVO Bioscience completed the acquisition of the Wisconsin Fertility Institute, which had over $5 million in revenue and $1.7 million in net income last year. This acquisition is expected to double the existing run rate of clinic operations.
• Transition to Healthcare Services: The company is shifting from a medical device focus to a healthcare services provider in the fertility market, aiming to capture more revenue and profit from treatment solutions.
• New Center Openings: The company plans to open a new INVO Center in Tampa within 60 to 90 days, further expanding its footprint.
• FDA Clearance: Received 510(k) clearance for a five-day incubation period for the INVOcell device, which is expected to enhance competitive positioning and marketing efforts.

3. Forward Guidance and Outlook

• Breakeven Target: The company aims to achieve operating cash flow breakeven in 2024, relying on incremental growth from existing clinics and the newly acquired Wisconsin clinic.
• Revenue Growth: Expected clinic revenue to build throughout 2023, particularly from the Wisconsin clinic and the Tampa center.
• Cost Management: Ongoing corporate expense reductions are anticipated to improve overall operating performance.

4. Bad News, Challenges, or Points of Concern

• Cash Position: The company has a limited cash reserve of approximately $112,000, which may pose liquidity risks.
• Debt Levels: The presence of $1.3 million in debt could impact financial flexibility.
• Market Competition: There is a competitive disadvantage due to previous misconceptions about INVOcell's success rates compared to traditional IVF, although the new FDA clearance aims to address this.

5. Notable Q&A Insights

• Impact of 510(k) Clearance: The clearance for a five-day incubation period is expected to enhance marketing efforts and improve patient outcomes, helping to attract more patients to clinics.
• Growth Assumptions for Breakeven: The breakeven target does not factor in additional acquisitions, focusing instead on organic growth from existing and newly opened clinics.
• Cost Reductions: Approximately 30% of corporate costs have been reduced, which is expected to be maintained moving forward.

Overall, INVO Bioscience is positioned for growth following its strategic acquisition and FDA clearance, though it faces challenges related to cash reserves and market competition.